Stage III Pancreatic Cancer Clinical Trial
Official title:
Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas
NCT number | NCT00253526 |
Other study ID # | CDR0000448825 |
Secondary ID | NCI-05-C-0158NCI |
Status | Withdrawn |
Phase | Phase 2 |
First received | November 11, 2005 |
Last updated | April 27, 2015 |
Verified date | December 2006 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine
hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.
PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see
how well they work compared to gemcitabine hydrochloride alone in treating patients who are
undergoing surgery for pancreatic cancer.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed adenocarcinoma of the pancreas - No evidence of distant metastasis on laparoscopy - No superior mesenteric artery or thrombosed superior mesenteric vein involvement - Superior mesenteric vein or portal vein involvement allowed - Evidence of a pancreatic mass by radiographic or endoscopic examination PATIENT CHARACTERISTICS: Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - WBC = 2,500/mm^3 - Absolute neutrophil count = 1,250/mm^3 - Platelet count = 100,000/mm^3 Hepatic - Hepatitis B surface antigen negative - Hepatitis C virus negative - No history of hepatic cirrhosis Renal - Creatinine = 2.0 mg/dL - Proteinuria negative or trace by urinalysis OR - Protein < 1 g on 24 hr urine collection - No active gross hematuria Cardiovascular - No severe congestive heart failure - No active ischemic heart disease - No ischemic changes on a cardiac thallium stress test - No uncontrolled hypertension (i.e., blood pressure = 150/100 mm Hg despite antihypertensive therapy) - No active coagulation disorder Pulmonary - No active gross hemoptysis Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during the adjuvant therapy part of trial - HIV negative - No active infection - No wound healing problem from recent invasive procedure - No significant history of medical illness that would preclude patient from undergoing an operative procedure - No other malignancy requiring systemic therapy PRIOR CONCURRENT THERAPY: Biologic therapy - Recovered from prior immunotherapy for pancreatic cancer - No prior bevacizumab Chemotherapy - Recovered from prior chemotherapy for pancreatic cancer - No prior gemcitabine hydrochloride Endocrine therapy - Recovered from prior hormonal therapy for pancreatic cancer Radiotherapy - Recovered from prior radiotherapy for pancreatic cancer - No prior radiotherapy to the pancreas Surgery - No prior definitive resection of the primary pancreatic tumor - Prior surgery, other than resection of the primary tumor, allowed Other - More than 3 weeks since prior systemic therapy for this cancer - No concurrent therapeutic anticoagulation causing elevated PT or PTT |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00020345 -
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
|
Phase 2 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT01068327 -
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00026104 -
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03899649 -
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
|
||
Terminated |
NCT01739439 -
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01821612 -
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
|
Early Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00323583 -
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A |